Eagle’s Eye View: Key Takeaways from ACC.25 Major Trials and Presentations

Apr 02, 2025   |  Kim A. Eagle, MD, MACC

Podcast
Print
Font Size
A
A
A
On this page:
Resources

In this week’s View, Dr. Eagle looks at the major trials and presentations from the recently concluded ACC.25 in Chicago. This episode includes coverage of practice-changing and practice-validating trials including:

  • Evolut Low Risk: Transcatheter aortic valve replacement (TAVR) noninferior to surgical aortic valve replacement (SAVR) at 5-Year Follow-Up
  • SMART-CHOICE 3: Clopidogrel shows benefit over aspirin monotherapy following percutaneous coronary intervention (PCI)
  • DAPA-TAVI: Dapagliflozin safe and effective in older adults with heart failure (HF) undergoing transcatheter aortic valve implantation (TAVI)
  • STRIDE: Semaglutide improves peripheral artery disease (PAD) outcomes
  • RIVAWAR: Rivaroxaban as effective as warfarin for post-myocardial infarction (MI) left ventricle (LV) thrombus
  • PI-CAT: Extended anticoagulant therapy with reduced-dose apixaban noninferior to full-dose in patients with active cancer and venous thromboembolism (VTE)

    • X Links:

Resources

Clinical Topics: Anticoagulation Management, Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Atherosclerotic Disease (CAD/PAD), Aortic Surgery, Interventions and Vascular Medicine, Vascular Medicine

Keywords: ACC Annual Scientific Session, ACC25, Transcatheter Aortic Valve Replacement, Interventional Cardiology, Stenosis, Percutaneous Coronary Intervention, Dual Anti-Platelet Therapy, Peripheral Arterial Disease, Semaglutide, Chronic Kidney Disease, Diabetes, Myocardial Infarction, Anticoagulants, Cancer, Thrombosis